May 2023—Sysmex Inostics and Genomic Testing Cooperative formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services, including Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services, to biopharma customers. The partnership brings together GTC’s proprietary genomic databases, technology in artificial intelligence, and DNA and RNA next-generation sequencing profiling with Sysmex Inostics’ worldwide commercial capabilities in biopharma therapeutic development and its Plasma-Safe-SeqS technology.
Read More »Home >> Tag Archives: Sysmex Inostics
Sysmex CRC kit gets approval in Japan
November 2019—Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBeam RAS CRC Kit, used for blood-based circulating tumor DNA molecular testing of mutations in the RAS gene for advanced colorectal cancer patients.
Read More »OncoBeam shows clinical value for melanoma patients
December 2018—Sysmex Inostics announced publication of a study in the Journal of Molecular Oncology (Rowe SP, et al. 2018;12[10]:1661–1672) highlighting the clinical value of blood-based ctDNA mutation testing to complement standard-of-care management of patients with advanced melanoma.
Read More »